---
figid: PMC9250860__jgo-33-e64-g001
pmcid: PMC9250860
image_filename: jgo-33-e64-g001.jpg
figure_link: /pmc/articles/PMC9250860/figure/F1/
number: Fig. 1
figure_title: AMBITION trial schema, adapted from Lee et al. []
caption: HRR, homologous recombination repair; PD-L1, program death ligand 1; HRD+,
  HRD positive (defined as presence of at least one mutation of 15 HRR pathway genes);
  HRDâˆ’, HRD negative; PD-L1+, PD-L1 positive (defined as tumor proportion score of
  25% or more); PLD, pegylated liposomal doxorubicin.
article_title: A step towards the ambition of precision oncology in recurrent ovarian
  cancer.
citation: Silvana Talisa Wijaya, et al. J Gynecol Oncol. 2022 Jul;33(4):e64.
year: '2022'

doi: 10.3802/jgo.2022.33.e64
journal_title: Journal of Gynecologic Oncology
journal_nlm_ta: J Gynecol Oncol
publisher_name: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic
  Oncology; Japan Society of Gynecologic Oncology

keywords:
---
